Trastuzumab emtansine is an antibody–drug conjugate that is effective in human epidermal growth factor receptor-2 expressing advanced breast cancer. Trastuzumab emtansine is generally well tolerated and grade 3–4 toxicities are rare. Pulmonary complications were rarely reported. Here we present a patient presenting with dyspnea after trastuzumab emtansine therapy and treated with a diagnosis of interstitial pneumonitis.
DawoodS, et al.Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol2010; 28: 92–98.
2.
Lewis PhillipsGD, et al.Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res2008; 68: 9280–9290.
3.
VermaS, et al.Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med2012; 367: 1783–1791.
4.
KropIE, et al.Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol2017; 18: 743–754.
5.
NaranjoCA, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
6.
AntoniouKM, et al.Interstitial lung disease. Eur Respir Rev2014; 23: 40–54.
7.
RomondEH, et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med2005; 353: 1673–1684.
CostaR, et al.Interstitial pneumonitis secondary to trastuzumab: a case report and literature review. Case Rep Oncol2017; 10: 524–530.
10.
AbulkhairOEl MeloukW. Delayed paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer. Case Rep Oncol2011; 4: 186–191.
11.
KuipEMullerE. Fatal pneumonitis after treatment with docetaxel and trastuzumab. Neth J Med2009; 67: 237–239.
12.
SugayaA, et al.Interstitial lung disease associated with trastuzumab monotherapy: a report of 3 cases. Mol Clin Oncol2017; 6: 229–232.
13.
BielopolskiD, et al.Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother2017; 29: 113–117.
14.
PerezEA, et al.Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE Study. J Clin Oncol2017; 35: 141–148.
15.
KwonY, et al.Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine: a case report. Chest2016; 149: e103–e105.
